Small company, disproportionate current wins: the period's actual events are big relative to the enterprise
The model's full reasoning — Q2 2023 call → NOWe need to determine if management describes specific business events that actually occurred in or around the recent period, that are large relative to the company's current size, and that have contributed only partially to reported results with most effect still ahead. The events must be real, already-occurred, and management must convey the disproportion. From the transcript: - KEDRAB sales increased significantly, with demand in the U.S. market. They mention that during the first six months, they experienced a significant increase in demand, and anticipate further momentum in the second half. They also mention that Kedrion extended the distribution agreement through 2026. This is a real event (extension) and increased sales. But is it large relative to company size? The company's total revenues for first half were $68.2M, and KEDRAB sales were part of that. They mention the U.S. market is estimated at $150M annually. But they don't explicitly say that this event is out of proportion to their size. They do say "significant increase" but that's not necessarily a disproportion. Also, the extension is a contract renewal, not a new large event. - The FDA approval to manufacture CYTOGAM at their Israeli facility, and Health Canada approval. This is a regulatory approval, not a business event like a contract or order. It's a capability, not a specific order. - The InnovAATe trial enrollment is ramping, but that's a clinical trial, not a business event. - The $60 million financing from FIMI is a financing event, but it's contingent on shareholder approval (they mention the meeting on August 29). So it's not yet closed. - They mention the acquisition of IgG products in late 2021, but that's not in the recent period.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| KOPN | Kopin Corporation | Q4 2023 | 2024-03-14 | C+ |
| NBTX | Nanobiotix S.A. | Q2 2023 | 2023-09-27 | D |
| GVP | GSE Systems, Inc. | Q1 2023 | 2023-05-15 | D |
| EVGO | EVgo, Inc. | Q2 2022 | 2022-08-09 | C+ |
| SYM | Symbotic Inc. | Q3 2022 | 2022-08-01 | B+ |
| VNRX | VolitionRx Limited | Q1 2022 | 2022-05-12 | F |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| FLUX | Flux Power Holdings, Inc. | Q2 2022 | 2022-02-10 | D |
| BFI | BurgerFi International, Inc. | Q3 2021 | 2021-11-12 | C |
| LIND | Lindblad Expeditions Holdings, Inc. | Q2 2017 | 2017-08-06 | C |
| ARAY | Accuray Incorporated | Q4 2016 | 2016-08-17 | B |
| GOGO | Gogo Inc. | Q1 2016 | 2016-05-06 | C+ |
LIND · Q2 2017 → YESThe question is about whether management describes specific business events that actually occurred recently, that are large relative to the company's size, with most of their effect still ahead. YES The transcript shows management describing the recent launch of the National Geographic Quest (first guests July 29, just after quarter-end) as a major milestone: "the next leg of that growth strategy is now firmly underway," "the most advanced passenger ship built in the U.S. in decades," and "we are now on the precipice of delivering on the investment thesis from 2015.
GVP · Q1 2023 → YESThe question is about whether management describes specific business events that actually occurred, large relative to the company's size, with most effect still ahead. YES The transcript shows management describing specific, already-awarded contracts and orders ($19.1 million in new awards, including a $28 million five-year renewal with U.S. government labs) that are framed as the highest in nearly three years and the highest backlog in over a year.
GOGO · Q1 2016 → YESThe question is about whether management describes specific business events that actually occurred, large relative to the company's size, with most effect still ahead. YES The transcript shows management describing the 2Ku awards exceeding 1000 aircraft as a major milestone that has taken flight, with the company now needing to accelerate deployment, increase production rates, and potentially secure additional capital to absorb the scale.